Extracorporeal membrane oxygenation (ECMO) system is a life supporting system providing cardiac and respiratory support to the patients suffering from severe respiratory failure. ECMO circuit comprises cannulas, pump, blender and oxygenator, which oxygenates the blood and remove carbon dioxide through extracorporeal gas exchange device referred to as membrane oxygenator. Potential indications for which ECMO is used includes severe acute respiratory distress syndrome (ARDS), acute hypercapnic respiratory failure, bridge lung transplantation, primary graft dysfunction post-lung transplantation, and pulmonary hypertension with right ventricular failure.
Global extracorporeal membrane oxygenation system market is estimated to be valued at US$ 316.5 million in 2022 and is expected to exhibit a CAGR of 5.3% during the forecast period (2022-2030).
Figure 1.Global Extracorporeal Membrane Oxygenation System Market Share (%), by Modality, 2022
Increasing prevalence of cardiovascular and respiratory disorders are expected to drive growth of the extracorporeal membrane oxygenation system market
Increasing cases of cardiovascular and respiratory disorders is one of the major factors that is boosting growth of the extracorporeal membrane oxygenation system (ECMO) system market. For instance, according to data provided by the Centers for Disease Control and Prevention, in February 2022, one person dies every 36 seconds in the U.S. from cardiovascular disease.
|Base Year:||2021||Market Size in 2022:||US$ 316.5 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2022 to 2030|
|Forecast Period 2022 to 2030 CAGR:||5.3%||2030 Value Projection:||US$ 476.8 Mn|
Medtronic, Getinge AB, LivaNova PLC, Terumo Corporation, XENIOS AG, OriGen Biomedical, EUROSETS NIPRO, and MicroPort Scientific Corporation
|Restraints & Challenges:||
Figure 2.Global Extracorporeal Membrane Oxygenation System Market Share (%), by Region, 2022
Industrial collaborations by key players in market are expected to drive market growth during the forecast period.
Industry players in market are adopting the strategy of collaboration focusing on development of products. For instance, in 2018, Medtronic, a leader in medical technology, services, and solutions, collaborated with Sayler Biomedical LLC, for development of the product Century heart Lung machine. Century heart lung machine has features, such as compact and sturdy design, easy to use components and affordable price.
Global Extracorporeal Membrane Oxygenation System Market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.
The COVID-19 pandemic had a positive impact on the global extracorporeal membrane oxygenation system market, owing to its use in patients infected with the COVID-19 infection, experiencing difficulty in breathing. For instance, in April 2020, the U.S. Food and Drug Administration (FDA) had issued guidance to provide a policy to help expand the availability of devices used in extracorporeal membrane oxygenation (ECMO) therapy to address the novel coronavirus (COVID-19, SARS-CoV-2) public health emergency. ECMO systems are used for long-term respiratory/cardiopulmonary failure and provide assisted extracorporeal circulation and physiologic gas exchange of the patient’s blood for more than six hours. The technology can oxygenate a severely sick COVID-19 pneumonia patient's blood without the need to transfer oxygen through fluid filled lungs. Thus the COVID-19 pandemic had a positive impact on the extracorporeal membrane oxygenation system market
Global Extracorporeal Membrane Oxygenation System Market: Key Developments
In May 2022, LivaNova PLC, a global medical technology company, acquired ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure
In January 2021, Braile Biomedica, an advanced manufacturer of medical-surgical and hospital products, launched SOLIS System, a product against COVID-19 in partnership with the Eldorado Institute, a non-profit research, development and innovation institution, and Embrapii, a social organization. The system consists of extracorporeal membrane oxygenation (ECMO), a form of extracorporeal breathing.
Global Extracorporeal Membrane Oxygenation System Market: Restraint
The major factors that hinder growth of the global extracorporeal membrane oxygenation system market include complications associated with the ECMO system such as internal bleeding, blood clotting or technical failure and high cost of the ECMO equipments.
Major players operating in the global extracorporeal membrane oxygenation system market include Medtronic, Getinge AB, LivaNova PLC, Terumo Corporation, XENIOS AG, OriGen Biomedical, EUROSETS NIPRO, and MicroPort Scientific Corporation.
Extracorporeal membrane oxygenation (ECMO) assists cardiopulmonary functions outside the body. Based on the location of drainage and reinfusion there are three different types of extracorporeal membrane oxygenation system which are arteriovenous, venoarterial, and venovenous. Whereas, on the bases of age, ECMO systems are classified into neonatal, pediatric and adult. . The location of drainage and reinfusion port of cannulas determines the modality of the ECMO system. If drainage and reinfusion both are from central veins it is referred as venovenous ECMO or if it is from vein to artery it is referred to as venoarterial ECMO. ECMO is helpful for people who are very ill with conditions of the lungs and heart, or who are awaiting for or recovering from a heart transplant. It may be used when other life support measures do not work. ECMO does not treat or cure a disease, but can assist the body temporarily when it is not able to provide the tissues with enough oxygen.
Growing number of congenital heart defects, increase demand for ECMO. For instance, according to American Heart Association, approximately 40,000 infants are born with a congenital heart defect in U.S. each year and around 2 to 3 million individuals are living with a congenital heart defect.
Growth of ECMO market is due to factors such as increasing prevalence of cardiovascular and chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), occupational lung disease or pulmonary hypertension. For instance, according to data published by the World Health Organization, in May 2022, chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, causing 3.23 million deaths in 2019.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.